pharma · Ulcerative Colitis · Multiple Myeloma
AbbVie Deutschland GmbH
AbbVie Deutschland GmbH & Co. KG
APONTIS PHARMA Deutschland is a pharma organization headquartered in Wiesbaden, DE. Primary therapeutic focus areas include Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Ar
Company details
- Status
- Public
- HQ
- Wiesbaden, DE
- Founded
- 2018
- Employees
- 101
- Programs
- 102
- Drugs
- 119
- Patents
- 23
Quick answer
APONTIS PHARMA Deutschland is a pharma organization headquartered in Wiesbaden, DE. Primary therapeutic focus areas include Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Arthritis, Metastatic Colorectal Cancer. NovaPharmaNews links 102 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (45), phase 2 (33), phase 1 (20).
Company snapshot
AbbVie Deutschland GmbH maintains 102 tracked programs across Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Arthritis, Metastatic Colorectal Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Migraine, Crohn's Disease (CD), Acute Myeloid Leukemia, Crohn's disease, Colorectal Cancer. Momentum score: n/a/100 (30-day delta: n/a). Public registry d
- 102 active pipeline program(s) linked via ClinicalTrials.gov.
- 23 US patent(s) indexed to this assignee profile.
- 102 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for AbbVie Deutschland GmbH. Not investment advice.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for AbbVie Deutschland GmbH.
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for AbbVie Deutschland GmbH.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is AbbVie Deutschland GmbH?
-
Is AbbVie Deutschland GmbH publicly traded?
-
What drugs does AbbVie Deutschland GmbH develop or market?
-
What are the latest developments for AbbVie Deutschland GmbH?
-
What therapeutic areas does AbbVie Deutschland GmbH focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.